🩺 Anti-Diabetic Medicines
Ernest Pharmaceutical is a trusted exporter of a wide range of high-quality anti-diabetic medicines. Our formulations are designed to provide effective glycemic control and are manufactured to meet international regulatory standards. Below is our featured product portfolio:
1. Metrose 500 Tablet
Composition: Metformin 500 mg
Type: Oral Diabetes Medicine (Biguanide)
Description: A first-line treatment for Type 2 diabetes, Metformin helps reduce glucose production in the liver and improves insulin sensitivity.
2. Sitazee M 1000 Tablet
Composition: Sitagliptin 50 mg + Metformin 1000 mg
Type: DPP-4 Inhibitor + Metformin Combination
Description: Combines the benefits of Sitagliptin for increased insulin release and Metformin for lowering hepatic glucose output—ideal for dual-action control.
3. Dapazee M 1000 XR Tablet
Composition: Dapagliflozin 10 mg + Metformin 1000 mg (Extended Release)
Type: SGLT2 Inhibitor + Extended Release Metformin
Description: A powerful combination that reduces glucose reabsorption in the kidneys while maintaining steady blood sugar levels with XR Metformin.
4. Glyzee M1 Tablet
Composition: Glimepiride 1 mg + Metformin 500 mg
Type: Sulfonylurea + Metformin Combination
Description: Enhances insulin secretion and improves insulin sensitivity, making it effective for patients requiring dual oral therapy.
5. Metrose 500 SR Tablet
Composition: Metformin 500 mg (Sustained Release)
Type: SR Metformin
Description: Offers gradual release of Metformin to ensure consistent glucose control and minimize gastrointestinal side effects.
6. Glyzee PM 2 Tablet
Composition: Glimepiride 2 mg + Pioglitazone 15 mg + Metformin 500 mg
Type: Sulfonylurea + Thiazolidinedione + Metformin Combination
Description: A triple combination that targets multiple pathways—ideal for advanced diabetic patients needing comprehensive control.
7. Glyzee 2 Tablet
Composition: Glimepiride 2 mg
Type: Sulfonylurea
Description: Stimulates the pancreas to produce more insulin; commonly used as monotherapy or in combination with Metformin.
8. Glyzee M3 SR Forte Tablet
Composition: Glimepiride 3 mg + Metformin 1000 mg (Prolonged Release)
Type: Sulfonylurea + PR Metformin Combination
Description: High-strength dual therapy with prolonged action, suitable for patients requiring sustained glycemic control.
9. Dapazee M 5/500 ER Tablet
Composition: Dapagliflozin 5 mg + Metformin 500 mg (Extended Release)
Type: SGLT2 Inhibitor + Extended Release Metformin
Description: Dual-action treatment that supports weight loss, lowers blood sugar, and reduces cardiovascular risk in Type 2 diabetes.
10. Dapazee 10 Antidiabetic Tablet
Composition: Dapagliflozin 10 mg
Type: SGLT2 Inhibitor
Description: An effective monotherapy for Type 2 diabetes, Dapagliflozin helps lower blood glucose by promoting renal glucose excretion.
North America:
United States, Canada, Mexico
Latin America:
Argentina, Brazil, Chile, Colombia, Mexico, Peru, Venezuela, Ecuador, Bolivia, Uruguay, Paraguay, Costa Rica, Panama, Guatemala, Honduras, El Salvador, Nicaragua, Belize, Cuba, Dominican Republic, Haiti, Jamaica, Trinidad and Tobago, and all other countries in the region.
Southern Africa:
South Africa, Namibia, Botswana, Zimbabwe, Lesotho, Eswatini (Swaziland), Angola, Zambia, Mozambique, Malawi, and neighboring countries.
Middle East:
Saudi Arabia, United Arab Emirates, Qatar, Kuwait, Bahrain, Oman, Iraq, Jordan, Lebanon, Syria, Yemen, Israel, Palestine, Iran, Turkey, and all other countries in the region.
Contact
exports@ernestpharmaceuticals.com
WhatsApp Number